Welcome to our dedicated page for bioAffinity Tech SEC filings (Ticker: BIAF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The bioAffinity Technologies, Inc. (BIAF) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq Capital Market issuer, bioAffinity Technologies files current reports, proxy statements, registration statements and financial reports that describe its biotechnology business focused on noninvasive diagnostics and early detection of lung cancer and other lung diseases.
Through its filings, investors can review Form 8-K current reports detailing material events such as College of American Pathologists (CAP) accreditation for its subsidiary Precision Pathology Laboratory Services, notifications of allowance for U.S. and international patents protecting the CyPath® Lung platform, presentations at major medical conferences and capital-raising transactions, including registered direct offerings under an effective Form S-3 shelf registration statement. These 8-Ks also summarize developments related to Nasdaq listing compliance and monitoring.
Definitive proxy statements filed on Schedule 14A outline governance and capital structure proposals, such as warrant exercise and anti-dilution provisions, preferred stock terms, amendments to equity incentive plans and potential non-public offerings under Nasdaq rules. Together with periodic reports, these documents help explain how bioAffinity Technologies manages its equity, financing options and incentive programs while advancing CyPath® Lung and its diagnostic platform.
On Stock Titan, AI-powered tools can assist in reviewing lengthy filings by highlighting key sections related to revenue sources, laboratory operations, patent portfolio, Nasdaq compliance and financing terms. Users can quickly locate disclosures about the marketing of CyPath® Lung as a Laboratory Developed Test through Precision Pathology Laboratory Services, CAP and CLIA credentials, and the scope of the company’s global patent estate. Real-time EDGAR updates ensure that new BIAF filings, including future 10-K annual reports, 10-Q quarterly reports, 8-K current reports and proxy materials, are surfaced promptly, while AI summaries help interpret complex legal and financial language.
bioAffinity Technologies filed an 8-K reporting that it has expanded its Medical and Scientific Advisory Board by appointing three nationally recognized pulmonary and lung cancer specialists: Dr. David Ost of MD Anderson Cancer Center, Dr. Daniel Sterman of NYU Langone Health, and Dr. J. Scott Ferguson of the University of Wisconsin School of Medicine and Public Health.
The company develops CyPath® Lung, a noninvasive diagnostic test for early detection of lung cancer in high-risk patients with small indeterminate pulmonary nodules. In clinical studies, CyPath® Lung showed 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer, supporting its role as an added tool to inform clinicians and potentially improve early-stage diagnosis.
bioAffinity Technologies, Inc. has scheduled its 2026 Annual Meeting of Stockholders for April 30, 2026 at its principal executive offices in San Antonio, Texas. The company plans to include at this meeting the proposals from a prior Special Meeting that was convened on December 19, 2025 but adjourned without business because a quorum of common stockholders was not present.
Stockholders who wish to bring business before the 2026 Annual Meeting or nominate directors must deliver written notice to the company’s principal executive offices by February 14, 2026, in accordance with the detailed requirements of the company’s Amended and Restated Bylaws.
bioAffinity Technologies, Inc. reported that its wholly owned laboratory subsidiary, Precision Pathology Laboratory Services, has successfully maintained its accreditation from the College of American Pathologists. The continued accreditation follows an on-site inspection, indicating the lab met the standards reviewed during that visit.
The company disclosed this development in connection with a press release, which is included as an exhibit to the report.
bioAffinity Technologies, Inc. reported that it will present a scientific poster titled “CyPath® Lung in Practice: From Uncertainty to Clarity and Confidence” at the American Cancer Society National Lung Cancer Roundtable on December 8, 2025. The poster highlights three clinical cases in which CyPath® Lung, a noninvasive sputum-based flow cytometry test, successfully identified Stage 1A lung cancer in patients whose presentations were atypical and diagnostically challenging. The company announced this upcoming presentation in a press release dated December 3, 2025, and has filed both the press release and the poster as exhibits.
bioAffinity Technologies, Inc. (BIAF) filed an 8-K reporting that it furnished a press release containing financial information for the quarter ended September 30, 2025. The company stated the press release is provided under Item 2.02 and is furnished, not filed, and will not be incorporated by reference into other SEC filings.
Exhibits include 99.1 (the press release dated November 14, 2025) and 104 (Cover Page Interactive Data File). The company’s securities listed are Common Stock (BIAF) and Tradeable Warrants (BIAFW) on The Nasdaq Stock Market LLC.
bioAffinity Technologies (BIAF) called a Special Meeting to approve multiple share-related actions. The Board asks stockholders to approve: issuing up to 271,500 shares upon exercise of August 2025 warrants; a warrant anti-dilution reset that could raise the exercisable amount up to 365,620 shares; and a Series B Preferred anti-dilution reset allowing up to 131,884 additional conversion shares. The Board also seeks to amend the 2024 Equity Incentive Plan to 750,000 shares from 66,666; authorize one or more non-public offerings of up to 10 million shares for up to $10,000,000 (at discounts up to 35%) through December 31, 2026; approve any Nasdaq Rule 5635 change of control arising from such offerings; and permit adjournment if needed.
As context, shares outstanding were 3,633,815 as of November 4, 2025. The company states the August 2025 warrants, if exercised for cash, could provide up to approximately $2.9 million in gross proceeds. The Board recommends “FOR” on all proposals.
bioAffinity Technologies (BIAF) filed an 8‑K announcing month‑over‑month growth in CyPath® Lung test volume. The company disclosed the update under Item 8.01 (Other Events) and furnished a detailed press release as Exhibit 99.1. The filing identifies the company’s listed securities on the Nasdaq Capital Market under symbols BIAF (common stock) and BIAFW (warrants). The report date is November 5, 2025.
bioAffinity Technologies reported that the Australian Patent Office has accepted its patent application AU 2019253111, titled “System and Method for Determining Lung Health.” The patent covers methods that combine flow cytometry with fluorescent probes and molecular tags that attach to specific cell types to detect cellular and molecular signatures of multiple lung diseases. The company issued a press release, attached as Exhibit 99.1.
bioAffinity Technologies (BIAF) called a Special Meeting to seek stockholder approval for multiple equity actions. The agenda includes authorizing the issuance of up to 271,500 shares upon exercise of August 2025 warrants, approving an anti-dilution reset that could raise the warrant share count by up to 365,620, and approving a similar anti-dilution reset for Series B Preferred that could add up to 131,884 conversion shares.
The Company also asks to amend its 2024 Equity Incentive Plan to increase the reserve to 750,000 shares and to authorize one or more non‑public offerings of up to 10 million shares for total consideration not exceeding $10,000,000, at discounts up to 35%, through December 31, 2026, along with related change‑of‑control approval under Nasdaq rules. Shares outstanding were 3,633,815 as of the record date. The Board recommends voting “FOR” each proposal.
bioAffinity Technologies reported it will present new research at CHEST 2025, the annual meeting of the American College of Chest Physicians. The company’s project manager for product development, Rossella Titone, PhD, will present the poster titled “The Effect of Sputum Storage and Shipping Temperature on Flow Cytometric Outcomes of Sputum-Based Diagnostic Tests.”
The presentation is scheduled for October 22, 2025 at 10:20 a.m. at poster board #4324. The company attached its press release and the full poster as Exhibits 99.1 and 99.2, which are incorporated by reference.